Constantine S Tam
Overview
Explore the profile of Constantine S Tam including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
224
Citations
8148
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bayraktar R, Tang Y, Dragomir M, Ivan C, Peng X, Fabris L, et al.
Sci Adv
. 2025 Feb;
11(8):eado2830.
PMID: 39970212
The mutational landscape of phylogenetically ultraconserved elements (UCEs), especially those in noncoding DNAs (ncUCEs), and their functional relevance in cancers remain poorly characterized. Here, we perform a systematic analysis of...
2.
Wang M, Jurczak W, Trneny M, Belada D, Wrobel T, Ghosh N, et al.
Lancet Oncol
. 2025 Feb;
26(2):200-213.
PMID: 39914418
Background: The combination of ibrutinib and venetoclax leverages complementary mechanisms of action and has shown promising clinical activity in mantle cell lymphoma (MCL). This study evaluated the efficacy and safety...
3.
Brown J, Li J, Eichhorst B, Lamanna N, OBrien M.D S, Tam C, et al.
Blood Adv
. 2025 Jan;
PMID: 39853273
Some CLL patients who develop progressive disease (PD) during treatment with covalent Bruton tyrosine kinase inhibitors (cBTKi) acquire pathway resistance mutations in BTK or PLCG2. Here, we report gene mutation...
4.
Wang L, Chung E, Wellard C, Barraclough A, Campbell B, Chong G, et al.
Blood Adv
. 2025 Jan;
PMID: 39825862
Tumour 'bulk' has historically been considered an important prognostic marker and clinical tool to guide treatment in patients with lymphoma. However, its use and definitions in trial designs varies significantly...
5.
Tam C, Balendran S, Blombery P
Blood
. 2025 Jan;
145(10):1005-1009.
PMID: 39808800
Bruton tyrosine kinase inhibitors (BTKis) are an established standard of care in chronic lymphocytic leukemia. The covalent BTKis ibrutinib, acalabrutinib, and zanubrutinib bind to BTK C481 and are all susceptible...
6.
Shadman M, Munir T, Robak T, Brown J, Kahl B, Ghia P, et al.
J Clin Oncol
. 2024 Dec;
43(7):780-787.
PMID: 39647999
JCO SEQUOIA (ClinicalTrials.gov identifier: NCT03336333) is a phase III, randomized, open-label trial that compared the oral Bruton tyrosine kinase inhibitor zanubrutinib to bendamustine plus rituximab (BR) in treatment-naïve patients with...
7.
Heyman B, Opat S, Wahlin B, Dimopoulos M, Dimopoulos M, Castillo J, et al.
Blood Adv
. 2024 Dec;
9(4):722-728.
PMID: 39626287
Peripheral neuropathy (PN) is a significant cause of morbidity associated with Waldenström macroglobulinemia (WM). The phase 3 ASPEN study compared the efficacy and safety of zanubrutinib with ibrutinib in patients...
8.
Luo M, Tan T, Trussart M, Poch A, Nguyen T, Speed T, et al.
Blood
. 2024 Oct;
144(26):2748-2761.
PMID: 39471335
Venetoclax, a first-in-class BH3 mimetic drug that targets B-cell lymphoma-2 (BCL-2), has improved the outcomes of patients with chronic lymphocytic leukemia (CLL). Early measurements of the depth of the venetoclax...
9.
10.
Lamanna N, Tam C, Woyach J, Alencar A, Palomba M, Zinzani P, et al.
EJHaem
. 2024 Oct;
5(5):929-939.
PMID: 39415923
Clinical bleeding events are reported here from 773 patients with B-cell malignancies receiving pirtobrutinib monotherapy from the phase 1/2 BRUIN study (ClinicalTrials.gov identifier: NCT03740529), either in the presence or absence...